What is TP-508?
TP-508 (TP508, rusalatide) is a synthetic 23-amino-acid peptide matching amino acids 508 through 530 of human prothrombin, the precursor of thrombin (Norfleet et al., 2000). It represents part of thrombin's receptor-binding domain (Oyamada et al., 2010) but lacks the catalytic site, keeping the RGD (Arg-Gly-Asp) sequence (Tsopanoglou et al., 2004).
As Chrysalin and rusalatide acetate, the thrombin peptide TP508 reached human trials in diabetic foot ulcers and distal radius fractures; a distal radius fracture study that a 2008 review describes as phase III missed its primary clinical endpoint (Carney and Olszewska-Pazdrak, 2008). Disguised Alpha supplies TP-508 as a lyophilized powder, 10MG per vial, for laboratory research use only. Nothing on this page is guidance for use in people.
TP-508 reference data
| Property | Value |
|---|---|
| Name | TP-508 |
| Also called | TP508, TP 508, rusalatide (INN), rusalatide acetate (USAN, the acetate salt), Chrysalin, thrombin peptide TP508 |
| Structure or sequence | H-Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-NH₂ (AGYKPDEGKRGDACEGDSGGPFV-NH₂): 23 residues, C-terminal amide, one cysteine, one RGD motif |
| Compound class | Synthetic thrombin-derived peptide (non-catalytic prothrombin fragment) |
| Molecular formula | C₉₇H₁₄₇N₂₉O₃₅S (peptide); acetate salt record: C₂₉₅H₄₄₉N₈₇O₁₀₉S₃, three peptide chains per two acetic acid molecules |
| Molecular weight | 2311.4 g/mol (peptide); 7054 g/mol (3:2 acetate salt record) |
| Form | Lyophilized powder, 10MG per vial |
| Testing | Third-party tested, with the certificate for each lot published on the product page and in the COA portal |
Name, alias, 10MG vial format and storage are from the product page, which links PubChem CID 91668177 (rusalatide acetate); sequence, formulas, weights are from that record and CID 16158206 (rusalatide, INN). PubChem's separate TP508 record, CID 155817508, is drawn as the C-terminal acid (C₉₇H₁₄₆N₂₈O₃₆S, 2312.4 g/mol), unlike the amide INN and acetate records. Use your lot's certificate and your own analysis for identity and content.
See it beside the other compounds on this site in the peptide molecular weight reference table.
What the research covers
Published work on TP-508 falls into six areas, each summarized below with its model. Most evidence is animal and cell data, and many papers list authors from the University of Texas Medical Branch group that characterized the peptide or from companies working on it.
Origin and receptor biology
In human fibroblasts, TP508 induced transcripts, including annexin V, that the PAR1-activating peptide SFLLRNP did not, pointing to a route separate from PAR1, the protease-activated thrombin receptor (Sower et al., 1999). In endothelial cells, surface-bound TP508 supported αvβ3 integrin-dependent attachment and migration, a variant with RAD in place of RGD was inactive, and soluble TP508 opposed several thrombin effects (Tsopanoglou et al., 2004). A study from Capstone Therapeutics reported RGD-dependent αvβ3 binding and nitric oxide production that an αvβ3-blocking antibody inhibited (Derkach et al., 2010). Models: human fibroblasts, endothelial cells and αvβ3-expressing kidney cells.
Skin wound closure in rats
In normal rats with full-thickness excisional wounds, one topical application of 0.1 µg TP508 left wounds on average 39% more closed than controls by day 7, with a faster early closure rate, more inflammatory cells within 24 hours and larger functional vessels in granulation tissue (Stiernberg et al., 2000).
In rat skin made ischemic with flaps or free grafts, the same application raised closure rates over the first 7 days by 30% in normal skin and bipedicle flaps, 50% in cranially based flaps and 225% in free grafts (Norfleet et al., 2000). Model: rats; both from the University of Texas Medical Branch group.
Bone repair in rats and rabbits
In a closed rat femoral fracture model, TP508 accelerated repair on destructive torsion testing, with more callus blood vessels on blinded histology and induction of early growth factor, inflammatory and angiogenesis-related genes (Wang et al., 2005). In rabbits, TP508 in PLGA microspheres raised the torsional strength of radial defects at 6 weeks and of critically sized ulnar defects at 9 weeks versus control microspheres in the opposite limb (Sheller et al., 2004).
Both papers list OrthoLogic Corp authors. An Istanbul University group gave 48 rats a single local injection of saline, 10 µg or 100 µg TP508 at the end of tibial distraction and found larger areas of new bone than with saline (Cakarer et al., 2010). Models: rats and rabbits.
Endothelial function and cardiac ischemia in pigs
In pigs with chronic myocardial ischemia, TP508 raised perfusion of ischemic regions up to 16-fold, doubled wall thickening relative to placebo and reversed impaired nitric oxide-mediated vasodilation; in human endothelial cells it raised nitric oxide output by 85% (Fossum et al., 2008).
In 14 Yucatan pigs with 60 minutes of coronary occlusion and 120 minutes of reperfusion, TP508 (a bolus, then an intravenous infusion) reduced infarct size and TUNEL staining, with no significant difference in global or regional left ventricular function (Osipov et al., 2009). In hypercholesterolemic pigs, the monomer and a dimer form both reduced infarct size versus vehicle (Oyamada et al., 2010). Models: pigs and human endothelial cells.
Radiation injury in mice
In male CD-1 mice given TP508 once, 24 hours after a lethal 9 Gy exposure, the peptide was reported to increase survival and delay mortality, with less crypt disintegration, more crypt cell proliferation and higher expression of the stem cell markers DCLK1 and LGR5 (Kantara et al., 2015). Because the TP508 peptide has a short plasma half-life, the group then tested PEGylated versions; PEG30k-TP508 extended half-life in mice about 19-fold with enhanced activity, and the paper describes TP508 as being developed as a potential nuclear countermeasure (McVicar et al., 2017). Model: mice.
Human trials as research history
A 60-subject randomized, double-blind, placebo-controlled phase I/II trial applied saline or one of two TP508 amounts (as Chrysalin) to diabetic foot ulcers. In the per-protocol population, TP508 more than doubled the incidence of complete ulcer closure, raised the mean closure rate about 80% and cut median time to 100% closure about 40%; adverse events were equal between groups (Fife et al., 2007).
A 2008 review that calls rusalatide acetate an investigational drug reports that, in a phase III distal radius fracture study, it significantly accelerated radiographic union but failed its primary clinical endpoint, time to removal of immobilization, across all randomized participants; a subset analysis in osteopenic women met it (Carney and Olszewska-Pazdrak, 2008).
A 2020 systematic review of 26 randomized growth factor and protein trials in diabetic foot ulcers found evidence lacking for all but epidermal growth factor and noted Chrysalin's 2014 discontinuation in dermatology (Mahdipour and Sahebkar, 2020). Models: people with diabetic foot ulcers or distal radius fractures.
Key studies
- Stiernberg J, et al. Wound Repair Regen. 2000. PMID 10886811. DOI 10.1046/j.1524-475x.2000.00204.x. Rat full-thickness wounds, one topical application versus saline: faster early closure.
- Sheller MR, et al. J Orthop Res. 2004. PMID 15304284. DOI 10.1016/j.orthres.2004.03.009. Rabbit radial and ulnar defects, PLGA microspheres versus contralateral controls: higher torsional strength.
- Fife C, et al. Wound Repair Regen. 2007. PMID 17244316. DOI 10.1111/j.1524-475X.2006.00181.x. Randomized, double-blind, placebo-controlled phase I/II trial in 60 participants with diabetic foot ulcers: more complete closure.
- Carney DH, Olszewska-Pazdrak B. Expert Opin Pharmacother. 2008. PMID 18803458. DOI 10.1517/14656566.9.15.2717. Clinical program review: describes a phase III fracture study that missed its primary endpoint.
- Osipov RM, et al. Ann Thorac Surg. 2009. PMID 19231390. DOI 10.1016/j.athoracsur.2008.12.021. Yucatan pigs, coronary ischemia and reperfusion: smaller infarcts, no significant difference in left ventricular function.
- Kantara C, et al. Lab Invest. 2015. PMID 26280221. DOI 10.1038/labinvest.2015.103. CD-1 mice after lethal 9 Gy irradiation: longer survival, preserved intestinal crypts.
Handling and storage of TP-508 lyophilized powder
General laboratory practice for this material:
- Store the lyophilized powder at -20°C, protected from light, until reconstitution (storage guidance on the product page).
- Let the sealed vial reach room temperature before opening to limit condensation.
- After reconstitution, keep the solution at 2 to 8°C, protected from light, and avoid freeze/thaw cycles (product page); single-use aliquots help with the last point.
- TP508 has been reported to convert readily to a dimer in aqueous solution (Oyamada et al., 2010), so analytical methods should separate monomer from dimer.
- Record the lot number and keep its certificate; identity, purity and measured content are separate tests, so check which ones it reports before quantitative work.
- For mass spectrometry, the amidated peptide C₉₇H₁₄₇N₂₉O₃₅S has a monoisotopic mass of 2310.03 Da.
Frequently asked questions
What is TP-508?
TP-508, usually written TP508 in papers, is a synthetic 23-amino-acid peptide copying residues 508 to 530 of human prothrombin (Derkach et al., 2010). It has been studied in cell, rodent, rabbit and pig models and in two human trial programs.
Is thrombin peptide TP508 the same as thrombin?
No. Thrombin is a clotting protease; TP508 is a fragment of its precursor that lacks the catalytic site but keeps the RGD sequence (Tsopanoglou et al., 2004). In fibroblasts it induced genes that a PAR1-activating peptide did not (Sower et al., 1999).
Are TP-508, TP 508, rusalatide and Chrysalin the same compound?
They refer to the same 23-residue sequence. PubChem files TP-508 under rusalatide (INN) and TP-508 acetate under rusalatide acetate (USAN), the salt the product page names, and one paper lists TP508, rusalatide acetate and Chrysalin together (Kantara et al., 2015).
Has TP-508 been tested in people?
Yes, as research history. A phase I/II diabetic foot ulcer trial reported faster ulcer closure with topical TP508 (Fife et al., 2007), and a phase III distal radius fracture study missed its primary clinical endpoint (Carney and Olszewska-Pazdrak, 2008). These reports describe the trial material, not research-grade TP-508.
How should TP-508 vials be stored?
Keep the powder at -20°C, protected from light; after reconstitution, keep the solution at 2 to 8°C, protected from light, and avoid freeze/thaw cycles, as listed on the product page.
Where can researchers buy TP-508?
Disguised Alpha lists TP-508 for laboratory research as a lyophilized 10MG vial, third-party tested, with each lot's certificate on the product page, which also shows current availability: TP-508.
Related compounds and guides
- TB-500 and its research guide
- BPC-157 and its research guide
- GHK-Cu and its research guide
- How to reconstitute lyophilized peptides and lyophilized peptides explained
- What is a COA? and the COA portal
This product is for research use only. It has not been evaluated for safety or effectiveness in humans. Not for human consumption. All products are intended for laboratory research purposes only.